| Literature DB >> 26288698 |
W Michael Seganish1, Thierry O Fischmann1, Brad Sherborne1, Julius Matasi1, Brian Lavey1, William T McElroy1, Deen Tulshian1, James Tata1, Christopher Sondey1, Charles G Garlisi1, Kristine Devito1, James Fossetta1, Daniel Lundell1, Xiaoda Niu1.
Abstract
We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors. Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate a new, potent, and kinase selective pyrimidin-4-one chemotype. This chemotype is exemplified by compound 16, which has potent IRAK4 inhibition activity (IC50 = 27 nM) and excellent kinase selectivity (>100-fold against 99% of 111 tested kinases), and compound 31, which displays potent IRAK4 activity (IC50 = 93 nM) and good rat bioavailability (F = 42%).Entities:
Keywords: IRAK4; inflammation; kinase inhibitor; structure-based drug design
Year: 2015 PMID: 26288698 PMCID: PMC4538434 DOI: 10.1021/acsmedchemlett.5b00279
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345